Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
← catalyst calendarNCT06052800 · readout in 22 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
78actual
Sites
5
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-13 | actual | When the study began enrolling |
| Primary completion | 2026-09-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-10 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Fabry Disease
Primary outcomes
what the primary-completion date above is the date OFCohort 1: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients
measured through study completion with a minimum of 2 years
Cohort 2: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients
measured up to 1.5 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed